Overview

• Okava announced trials for OKV‑119, a long‑acting implant using the GLP‑1 mimic exenatide, after earlier safety testing in cats and with dog studies now planned.
• Human GLP‑1 drugs such as semaglutide do not work in dogs, so developers are pursuing species‑specific alternatives delivered by a chip‑sized device designed for roughly twice‑yearly dosing.
• Okava’s chief executive says the goal is to cut excessive begging and scavenging while preserving normal interest in meals, addressing concerns that appetite loss can signal illness.
• Veterinary and welfare voices urge diet and exercise as first‑line care, note limited evidence for implants, and cite the poor reception of the 2007 appetite‑suppressant Slentrol due to behavior changes.
• Rival efforts include research by Vivani Medical and a related pet‑health acquisition by Better Choice, set against data showing about half of UK dogs are overweight.